翰宇藥業(300199.SZ):10月30日利拉魯肽注射液迎來大規模發貨 貨款總值1.03億元
格隆匯11月4日丨翰宇藥業(300199.SZ)在投資者互動平台表示,10月30日,公司利拉魯肽注射液迎來了大規模發貨,本次貨款總值1.03億元人民幣,是公司於2023年11月3日公吿的商業批量訂單,未來公司將按照協議約定,與Hikma維持長期獨家合作關係,根據美國銷售市場需求,持續推進後續訂單發貨,並獲得兩位數的銷售利潤分成。除該筆訂單外,公司將根據項目進度陸續發出後續訂單,未來訂單履約情況請關注公司公開信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.